From: Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes
Description | VORI | CASPO | FLUC | ITRA | AMB | POSA | MICA | ANID |
---|---|---|---|---|---|---|---|---|
Used drug at least once (%) | 292 (70.87) | 161 (39.08) | 117 (28.40) | 34 (8.25) | 53 (12.86) | 3 (0.73) | 13 (3.16) | 9 (2.18) |
Used as initial monotherapy (%) (N = 354) | 166 (46.89) | 63 (17.80) | 98 (27.68) | 12 (3.39) | 12 (3.39) | 0 (0.00) | 2 (0.56) | 1 (0.28) |
Used as initial combination therapy (%) (N = 58) | 53 (91.38) | 38 (65.51) | 4 (6.90) | 10 (12.50) | 9 (11.25) | 3 (5.08) | 5 (8.62) | 5 (8.62) |
Length of initial therapy, days (SD) | 12.1 (12.3) | 9.1 (8.4) | 6.0 (4.7) | 8.4 (11.3) | 7.3 (8.3) | 14.3 (18.0) | 7.7 (6.6) | 10.6 (10.3) |
Length of initial therapy (Survivors) | 12.8 (12.6) | 10.9 (7.7) | 6.7 (5.0) | 9.4 (12.6) | 7.1 (6.9) | 14.3 (18.0) | 8.7 (7.8) | 11.3 (10.8) |
Length of initial therapy (Non-survivors) | 11.2 (12.0) | 7.2 (8.8) | 6.4 (4.5) | 6.1 (7.2) | 7.4 (9.1) | - | 6.5 (5.2) | 5.0 (−) |
Mortality (% who received drug at least once) | 125 (42.81) | 79 (49.07) | 66 (48.89) | 10 (29.41) | 33 (62.26) | 0 (0.00) | 6 (46.15) | 1 (11.11) |
Hospital admission to discharge, days (SD) | 27.8 (26.3) | 31.1 (31.1) | 33.9 (24.2) | 28.9 (19.5) | 30.7 (25.2) | 31.0 (21.2) | 25.3 (17.0) | 32.8 (20.7) |
Drug initiation to discharge, days (SD) | 19.2 (21.7) | 21.0 (26.1) | 25.1 (22.4) | 21.7 (16.3) | 23.2 (23.2) | 24.0 (18.0) | 20.5 (18.4) | 26.3 (15.3) |